Red color represents old content. It may be empty showing addition in the new version.
Green color represents new content. It may be empty showing deletion in the new version.
Inline
Side by side
Added new contents,
deleted old contents,contents that are not changed.
New table contents
New table contents
Old table contents
Old table contents
Unchanged contents
Unchanged contents
Added new contents, contents that are not changed.
Deleted old contents, contents that are not changed.
Old table contents
Old table contents
Unchanged contents
Unchanged contents
New table contents
New table contents
Unchanged contents
Unchanged contents
Protocol summary
The study group are full-term infants without risk factors, which were divided into 2 groups "phototherapy with zinc sulfate" and "phototherapy with placebo" based on the sample size of 320 people and randomization by means of boxes of 4 people, and the study was conducted in a double-blind manner, will be done.
The study group are infants without risk factors, which were divided into 2 groups "phototherapy with zinc sulfate" and "phototherapy alonely" based on the sample size of 120 people and randomization by means of boxes of 4 people, and the study was conducted in a double-blind manner, will be done.
The study group are full-term infants without risk factors, which were divided into 2 groups "phototherapy with zinc sulfate" and "phototherapy with placeboalonely" based on the sample size of 320120 people and randomization by means of boxes of 4 people, and the study was conducted in a double-blind manner, will be done.
گروه مورد مطالعه نوزادان ترم بدون ریسک فاکتور هستند که بر اساس حجم نمونه 320 نفری و تصادفی سازی به وسیله ی باکس های 4 نفری، به 2 گروه "فتوتراپی همراه با زینک سولفات" و "فتوتراپی با پلاسبو" تقسیم شده و به صورت دوسوکور مطالعه انجام می گیرد.
گروه مورد مطالعه نوزادان بدون ریسک فاکتور هستند که بر اساس حجم نمونه 120 نفری و تصادفی سازی به وسیله ی باکس های 4 نفری، به 2 گروه "فتوتراپی همراه با زینک سولفات" و "فتوتراپی به تنهایی" تقسیم شده و به صورت دوسوکور مطالعه انجام می گیرد.
گروه مورد مطالعه نوزادان ترم بدون ریسک فاکتور هستند که بر اساس حجم نمونه 320120 نفری و تصادفی سازی به وسیله ی باکس های 4 نفری، به 2 گروه "فتوتراپی همراه با زینک سولفات" و "فتوتراپی با پلاسبوبه تنهایی" تقسیم شده و به صورت دوسوکور مطالعه انجام می گیرد.
The criteria for the inclusion of infants in the study include all full-term infants with indirect hyperbilirubinemia with pathological total bilirubin levels for age and time of birth. The criteria for the exclusion of infants from the study include those that can affect the result of the study as a confounding factor; For example, liver diseases and all diseases that affect the level of bilirubin, or babies who take supplements containing zinc.
The criteria for the inclusion of infants in the study include all infants with indirect hyperbilirubinemia with pathological total bilirubin levels for age and time of birth. The criteria for the exclusion of infants from the study include those that can affect the result of the study as a confounding factor; For example, liver diseases and all diseases that affect the level of bilirubin, or babies who take supplements containing zinc.
The criteria for the inclusion of infants in the study include all full-term infants with indirect hyperbilirubinemia with pathological total bilirubin levels for age and time of birth. The criteria for the exclusion of infants from the study include those that can affect the result of the study as a confounding factor; For example, liver diseases and all diseases that affect the level of bilirubin, or babies who take supplements containing zinc.
معیار های ورود نوزادان به مطالعه شامل تمامی نوزادان ترم که مبتلا به هیپربیلیروبینمی غیرمستقیم با میزان بیلیروبین توتال پاتولوژیک برای سن و ساعت تولدمی باشد. معیار های خروج نوزادان از مطالعه شامل مواردی است که می تواند به عنوان عامل مخدوش کننده نتیجه مطالعه را تحت تاثیر قرار دهد؛ به عنوان مثال بیماری های کبدی و تمامی بیماری هایی که سطح بیلی روبین را تحت تاثیر قرار می دهد و یا نوزادانی که مکمل های حاوی زینک مصرف می کنند.
معیار های ورود نوزادان به مطالعه شامل تمامی نوزادان مبتلا به هیپربیلیروبینمی غیرمستقیم با میزان بیلیروبین توتال پاتولوژیک برای سن و ساعت تولدمی باشد. معیار های خروج نوزادان از مطالعه شامل مواردی است که می تواند به عنوان عامل مخدوش کننده نتیجه مطالعه را تحت تاثیر قرار دهد؛ به عنوان مثال بیماری های کبدی و تمامی بیماری هایی که سطح بیلی روبین را تحت تاثیر قرار می دهد و یا نوزادانی که مکمل های حاوی زینک مصرف می کنند.
معیار های ورود نوزادان به مطالعه شامل تمامی نوزادان ترم که مبتلا به هیپربیلیروبینمی غیرمستقیم با میزان بیلیروبین توتال پاتولوژیک برای سن و ساعت تولدمی باشد. معیار های خروج نوزادان از مطالعه شامل مواردی است که می تواند به عنوان عامل مخدوش کننده نتیجه مطالعه را تحت تاثیر قرار دهد؛ به عنوان مثال بیماری های کبدی و تمامی بیماری هایی که سطح بیلی روبین را تحت تاثیر قرار می دهد و یا نوزادانی که مکمل های حاوی زینک مصرف می کنند.
The studied intervention is zinc sulfate syrup, which is administered orally at the rate of 1 cc per kilogram of the baby's body weight for 48 hours. The placebo intervention is sucrose syrup at the rate of 1 cc per kilogram of the baby's body weight.
The studied intervention is zinc sulfate (syrup 5 mg per 5 cc), which is administered orally at the rate of 1 mg per kilogram of the baby's body weight for 48 hours.
The studied intervention is zinc sulfate (syrup 5 mg per 5 cc), which is administered orally at the rate of 1 ccmg per kilogram of the baby's body weight for 48 hours. The placebo intervention is sucrose syrup at the rate of 1 cc per kilogram of the baby's body weight.
مداخله مورد مطالعه شربت زینک سولفات که به صورت خوراکی و به میزان 1 سی سی به ازای هر کیلوگرم وزن بدن نوزاد به مدت 48 ساعت تجویز می شود. مداخله پلاسبو شربت سوکروز به میزان ۱ سی سی به ازای هر کیلوگرم وزن بدن نوزاد می باشد.
مداخله مورد مطالعه زینک سولفات (شربت 5 میلی گرم زینک سولفات در هر 5 سی سی) که به صورت خوراکی و به میزان 1 سی سی به ازای هر کیلوگرم وزن بدن نوزاد به مدت 48 ساعت تجویز می شود.
مداخله مورد مطالعه زینک سولفات (شربت 5 میلی گرم زینک سولفات در هر 5 سی سی) که به صورت خوراکی و به میزان 1 سی سی به ازای هر کیلوگرم وزن بدن نوزاد به مدت 48 ساعت تجویز می شود. مداخله پلاسبو شربت سوکروز به میزان ۱ سی سی به ازای هر کیلوگرم وزن بدن نوزاد می باشد.
General information
Used
Not used
usednused
Parallel
Factorial
paralfacto
empty
120
120
empty
2024-08-22, 1403/06/01
2024-08-22 00:00:00
empty
2025-11-22, 1404/09/01
2025-11-22 00:00:00
empty
2025-11-22, 1404/09/01
2025-11-22 00:00:00
empty
Updating sample number and study duration
Updating sample number and study duration
empty
به روز رسانی حجم نمونه و طول مدت پژوهش
به روز رسانی حجم نمونه و طول مدت پژوهش
بررسی اثربخشی زینک سولفات در طول مدت نیاز نوزاد مبتلا به زردی توزادی به فتوتراپی
بررسی اثربخشی زینک سولفات در طول مدت نیاز نوزاد مبتلا به زردی نوزادی به فتوتراپی
بررسی اثربخشی زینک سولفات در طول مدت نیاز نوزاد مبتلا به زردی توزادینوزادی به فتوتراپی
All full-term babies without risk factors born with Neonatal Jaundice
All infants without risk factors born with Neonatal Jaundice
All full-term babiesinfants without risk factors born with Neonatal Jaundice
کلیه نوزادان فول ترم بدون ریسک فاکتور متولد شده با زردی نوزادی
کلیه نوزادان بدون ریسک فاکتور متولد شده با زردی نوزادی
کلیه نوزادان فول ترم بدون ریسک فاکتور متولد شده با زردی نوزادی
The mentioned randomization is carried out by the researcher and also the solutions used in both interventions are similar in terms of color, smell and taste.
The mentioned randomization is carried out by the researcher.
The mentioned randomization is carried out by the researcher and also the solutions used in both interventions are similar in terms of color, smell and taste.
انجام تصادفی سازی ذکر شده به وسیله ی محقق می باشد و همچنین محلول های مورد استفاده در هر دوم مداخله از نظر رنگ، بو و مزه مشابه یکدیگر می باشند.
انجام تصادفی سازی ذکر شده به وسیله ی محقق می باشد
انجام تصادفی سازی ذکر شده به وسیله ی محقق می باشد و همچنین محلول های مورد استفاده در هر دوم مداخله از نظر رنگ، بو و مزه مشابه یکدیگر می باشند.
Primary outcomes
#1
Measurement of serum total bilirubin level at the beginning of the study (before the start of the intervention), 2 and 14 days after the start of oral zinc sulfate intake.
Measurement of serum total bilirubin level at the beginning of the study (before the start of the intervention), 24, 48 and 72 hours after the start of oral zinc sulfate intake.
Measurement of serum total bilirubin level at the beginning of the study (before the start of the intervention), 224, 48 and 14 days72 hours after the start of oral zinc sulfate intake.
اندازه گیری سطح بیلی روبین توتال سرم در ابتدای مطالعه (قبل از شروع مداخله)، 2 و 14 روز پس از شروع مصرف زینک سولفات خوراکی
اندازه گیری سطح بیلی روبین توتال سرم در ابتدای مطالعه (قبل از شروع مداخله)، 24، 48 و 72 ساعت پس از شروع مصرف زینک سولفات خوراکی
اندازه گیری سطح بیلی روبین توتال سرم در ابتدای مطالعه (قبل از شروع مداخله)، 224، 48 و 14 روز72 ساعت پس از شروع مصرف زینک سولفات خوراکی
#2
Zinc Sulfate level in serum
empty
Zinc Sulfate level in serum
سطح زینک سولفات سرم
empty
سطح زینک سولفات سرم
Immediately before and after phototherapy depending on the duration of phototherapy
empty
Immediately before and after phototherapy depending on the duration of phototherapy
بلافاصله قبل و بعد از فتوتراپی بسته به مدت زمان انجام فتوتراپی
empty
بلافاصله قبل و بعد از فتوتراپی بسته به مدت زمان انجام فتوتراپی
Blood examination
empty
Blood examination
آزمایش خون
empty
آزمایش خون
Intervention groups
#1
Intervention group: Receiving oral zinc sulfate syrup 1 cc/kg, each cc containing 1 mg of zinc while performing phototherapy, which is checked for 48 hours.
Intervention group: Receiving oral zinc sulfate syrup 1 cc/kg, each 5 cc containing 5 mg of zinc while performing phototherapy, which is prescribed for 48 hours.
Intervention group: Receiving oral zinc sulfate syrup 1 cc/kg, each 5 cc containing 15 mg of zinc while performing phototherapy, which is checkedprescribed for 48 hours.
گروه مداخله: دریافت شربت زینک سولفات خوراکی 1cc/kg هر سی سی حاوی 1 میلی گرم زینک ضمن انجام فتوتراپی که به مدت 48 ساعت بررسی می شود.
گروه مداخله: دریافت شربت زینک سولفات خوراکی 1cc/kg هر 5 سی سی حاوی 5 میلی گرم زینک ضمن انجام فتوتراپی که به مدت 48 ساعت تجویز می شود.
گروه مداخله: دریافت شربت زینک سولفات خوراکی 1cc/kg هر 5 سی سی حاوی 15 میلی گرم زینک ضمن انجام فتوتراپی که به مدت 48 ساعت بررسیتجویز می شود.
#2
Placebo
Treatment - Devices
placebotreatment-devices
Control group: Receiving a placebo of sucrose syrup with a concentration of 1cc/kg while performing phototherapy
Control group: Receiving Phototherapy alonely
Control group: Receiving a placebo of sucrose syrup with a concentration of 1cc/kg while performing phototherapyPhototherapy alonely
گروه کنترل: دریافت پلاسبو شربت سوکروز با غلظت 1cc/kg ضمن انجام فتوتراپی
گروه کنترل: انجام فتوتراپی به تنهایی
گروه کنترل: دریافت پلاسبو شربت سوکروز با غلظت 1cc/kg ضمن انجام فتوتراپی به تنهایی
Sponsors / Funding sources
#1
Name of organization / entity - English:
Name of organization / entity - Persian:
Full name of responsible person - English: Ali Akbari Sari
Full name of responsible person - Persian: علی اکبری ساری
Street address - English: Corner of Qods St., Keshavarz Blvd., Tehran, Iran.
Street address - Persian: بلوار کشاورز، نبش خیابان قدس، سازمان مرکزی دانشگاه، طبقه ششم معاونت تحقیقات و فناوری
City - English: Tehran
City - Persian: تهران
Province: Tehran
Country: Iran (Islamic Republic of)
Postal code: 1417653761
Phone: +98 21 8163 3685
Fax:
Email: vcr@sina.tums.ac.ir
Web page address: https://vcr.tums.ac.ir/
Name of organization / entity - English:
Name of organization / entity - Persian:
Full name of responsible person - English: Ramin Kordi
Full name of responsible person - Persian: رامین کردی
Street address - English: Corner of Qods St., Keshavarz Blvd., Tehran, Iran.
Street address - Persian: بلوار کشاورز، نبش خیابان قدس، سازمان مرکزی دانشگاه، طبقه ششم معاونت تحقیقات و فناوری
City - English: Tehran
City - Persian: تهران
Province: Tehran
Country: Iran (Islamic Republic of)
Postal code: 1417653761
Phone: +98 21 8163 3685
Fax:
Email: vcr@sina.tums.ac.ir
Web page address: https://vcr.tums.ac.ir/
Name of organization / entity - English: Name of organization / entity - Persian: Full name of responsible person - English: Ali Akbari SariRamin Kordi Full name of responsible person - Persian: علی اکبری ساریرامین کردی Street address - English: Corner of Qods St., Keshavarz Blvd., Tehran, Iran. Street address - Persian: بلوار کشاورز، نبش خیابان قدس، سازمان مرکزی دانشگاه، طبقه ششم معاونت تحقیقات و فناوری City - English: Tehran City - Persian: تهران Province: Tehran Country: Iran (Islamic Republic of) Postal code: 1417653761 Phone: +98 21 8163 3685 Fax: Email: vcr@sina.tums.ac.ir Web page address: https://vcr.tums.ac.ir/
Protocol summary
Study aim
Investigating the simultaneous effect of phototherapy with oral zinc sulfate on the amount of bilirubin change in babies with hyperbilirubinemia and the duration of their treatment.
Design
The study group are infants without risk factors, which were divided into 2 groups "phototherapy with zinc sulfate" and "phototherapy alonely" based on the sample size of 120 people and randomization by means of boxes of 4 people, and the study was conducted in a double-blind manner, will be done.
Settings and conduct
The method of conducting the study is double-blind, which is carried out in the Neonatal and Neonatal Intensive Care Unit of Baharlou Hospital with the blinding of the ward nurse and the parents of the hospitalized baby. The blinding of the study is done by dividing the babies into 4 boxes and determining the intervention for each baby based on the available possibilities and based on rolling the dice which has 6 states, based on which the baby is given zinc sulfate syrup or sucrose.
Participants/Inclusion and exclusion criteria
The criteria for the inclusion of infants in the study include all infants with indirect hyperbilirubinemia with pathological total bilirubin levels for age and time of birth. The criteria for the exclusion of infants from the study include those that can affect the result of the study as a confounding factor; For example, liver diseases and all diseases that affect the level of bilirubin, or babies who take supplements containing zinc.
Intervention groups
The studied intervention is zinc sulfate (syrup 5 mg per 5 cc), which is administered orally at the rate of 1 mg per kilogram of the baby's body weight for 48 hours.
Main outcome variables
The amount of time and frequency required to perform phototherapy if zinc sulfate is prescribed for infants.
General information
Reason for update
Updating sample number and study duration
Acronym
IRCT registration information
IRCT registration number:IRCT20230914059430N1
Registration date:2024-01-29, 1402/11/09
Registration timing:prospective
Last update:2026-09-14, 1405/06/23
Update count:1
Registration date
2024-01-29, 1402/11/09
Registrant information
Name
Asghar Ghorbani
Name of organization / entity
Country
Iran (Islamic Republic of)
Phone
+98 912 321 1189
Email address
aghorbani@sina.tums.ac.ir
Recruitment status
Recruitment complete
Funding source
Expected recruitment start date
2024-02-20, 1402/12/01
Expected recruitment end date
2025-08-23, 1404/06/01
Actual recruitment start date
2024-08-22, 1403/06/01
Actual recruitment end date
2025-11-22, 1404/09/01
Trial completion date
2025-11-22, 1404/09/01
Scientific title
Investigating the effectiveness of Zinc Sulfate during the duration of the need for Phototherapy in infants with Congenital Jaundice
Public title
Investigating the simultaneous effect of Phototherapy with oral Zinc Sulfate on the amount of Bilirubin change in infants with Hyperbilirubinemia and the duration of their treatment in Baharlou Hospital.
Purpose
Treatment
Inclusion/Exclusion criteria
Inclusion criteria:
All infants without risk factors born with Neonatal Jaundice
Exclusion criteria:
Lack of parental consent
The presence of major risk factors in the baby, including Cardiovascular, Pulmonary, Renal defects, etc.
Age
From 1 day old to 14 days old
Gender
Both
Phase
2
Groups that have been masked
Participant
Care provider
Sample size
Target sample size:
320
Actual sample size reached:
120
Randomization (investigator's opinion)
Randomized
Randomization description
The randomization of the study is done in groups of 4 babies in one box, and according to the 2 possible interventions, 6 modes are considered for these boxes, and the status of each box is determined by throwing a dice.
Blinding (investigator's opinion)
Double blinded
Blinding description
The mentioned randomization is carried out by the researcher.
Placebo
Not used
Assignment
Factorial
Other design features
Secondary Ids
empty
Ethics committees
1
Ethics committee
Name of ethics committee
Tehran University of Medical Science
Street address
Keshavarz Blvd
City
Tehran
Province
Tehran
Postal code
1936893813
Approval date
2024-01-21, 1402/11/01
Ethics committee reference number
IR.TUMS.MEDICINE.REC.1402.575
Health conditions studied
1
Description of health condition studied
Congenital Jaundice
ICD-10 code
P59
ICD-10 code description
Neonatal jaundice from other and unspecified causes
Primary outcomes
1
Description
Total Bilirubin
Timepoint
Measurement of serum total bilirubin level at the beginning of the study (before the start of the intervention), 24, 48 and 72 hours after the start of oral zinc sulfate intake.
Method of measurement
Blood examination
Secondary outcomes
1
Description
The duration of receiving phototherapy
Timepoint
Up to 14 days after the study
Method of measurement
Medical record
2
Description
The length of hospitalization
Timepoint
Up to 14 days after the study
Method of measurement
Medical record
Intervention groups
1
Description
Intervention group: Receiving oral zinc sulfate syrup 1 cc/kg, each 5 cc containing 5 mg of zinc while performing phototherapy, which is prescribed for 48 hours.
Category
Treatment - Drugs
2
Description
Control group: Receiving Phototherapy alonely
Category
Treatment - Devices
Recruitment centers
1
Recruitment center
Name of recruitment center
Baharlou Hospital
Full name of responsible person
Asghar Ghorbani
Street address
Behdari St., Rahahan Sq., Tehran.
City
Tehran
Province
Tehran
Postal code
1339973111
Phone
+98 21 5565 8500
Fax
+98 21 5564 8189
Email
baharloo@sina.tums.ac.ir
Web page address
https://baharloo.tums.ac.ir/
Sponsors / Funding sources
1
Sponsor
Name of organization / entity
Tehran University of Medical Sciences
Full name of responsible person
Ramin Kordi
Street address
Corner of Qods St., Keshavarz Blvd., Tehran, Iran.
City
Tehran
Province
Tehran
Postal code
1417653761
Phone
+98 21 8163 3685
Email
vcr@sina.tums.ac.ir
Web page address
https://vcr.tums.ac.ir/
Grant name
Grant code / Reference number
Is the source of funding the same sponsor organization/entity?
Yes
Title of funding source
Tehran University of Medical Sciences
Proportion provided by this source
100
Public or private sector
Public
Domestic or foreign origin
Domestic
Category of foreign source of funding
empty
Country of origin
Type of organization providing the funding
Academic
Person responsible for general inquiries
Contact
Name of organization / entity
Tehran University of Medical Sciences
Full name of responsible person
Asghar Ghorbani
Position
Associate professor
Latest degree
Specialist
Other areas of specialty/work
Pediatrics
Street address
Keshavarz Blvd.
City
Tehran
Province
Tehran
Postal code
1417653761
Phone
+98 912 321 1189
Fax
Email
aghorbani@sina.tums.ac.ir
Person responsible for scientific inquiries
Contact
Name of organization / entity
Tehran University of Medical Sciences
Full name of responsible person
Asghar Ghorbani
Position
Associate professor
Latest degree
Specialist
Other areas of specialty/work
Pediatrics
Street address
Keshavarz Blvd.
City
Tehran
Province
Tehran
Postal code
1417653761
Phone
+98 912 321 1189
Fax
Email
aghorbani@sina.tums.ac.ir
Person responsible for updating data
Contact
Name of organization / entity
Tehran University of Medical Sciences
Full name of responsible person
Asghar Ghorbani
Position
Associate professor
Latest degree
Specialist
Other areas of specialty/work
Pediatrics
Street address
Keshavarz Blvd.
City
Tehran
Province
Tehran
Postal code
1417653761
Phone
+98 912 321 1189
Fax
Email
aghorbani@sina.tums.ac.ir
Sharing plan
Deidentified Individual Participant Data Set (IPD)
Yes - There is a plan to make this available
Study Protocol
No - There is not a plan to make this available
Statistical Analysis Plan
Yes - There is a plan to make this available
Informed Consent Form
Yes - There is a plan to make this available
Clinical Study Report
Yes - There is a plan to make this available
Analytic Code
No - There is not a plan to make this available
Data Dictionary
No - There is not a plan to make this available
Title and more details about the data/document
All potential data can be shared after de-identifying individuals after contacting the corresponding author.
When the data will become available and for how long
The beginning of the access period from 2026
To whom data/document is available
Researchers, Doctors and Health Decision Makers
Under which criteria data/document could be used
If any data is not reported in the text of the final report and the addressee needs it, this information will be provided to the requester if it is not about the confidential information of the patients.
From where data/document is obtainable
The manager Dr. Ghorbani
What processes are involved for a request to access data/document